Editor's pick: Our biggest health stories of 2023

Health channel editor Nicoletta Lanese looks back on some of our standout health stories from the past year.

illustration depicts amyloid-beta peptides, the building blocks of amyloid-beta plaques, building up in the brain among individual neurons
A newly approved drug targets sticky plaques of protein in the brain to treat Alzheimer's.
(Image credit: selvanegra via Getty Images)

This year brought the the approval of medicines that could be paradigm-shifting: January brought a new drug for Alzheimer's that's only the second of its kind, May saw the first-ever gene therapy for a rare, debilitating skin-blister disorder, and as of June, psychedelics can now be used as psychiatric treatments in Australia. (With trials ongoing in the U.S., we could be close behind on that last one.)

But arguably, the most formative development we witnessed in medicine this year was the approval of the world's first therapy built upon the gene-editing tool CRISPR.

Latest Videos From
Nicoletta Lanese
Channel Editor, Health

Nicoletta Lanese is the health channel editor at Live Science and was previously a news editor and staff writer at the site. She is a recipient of the 2026 AHCJ International Health Study Fellowship, with a project focused on antibiotic stewardship practices in Japan and the U.S. They hold a graduate certificate in science communication from UC Santa Cruz and degrees in neuroscience and dance from the University of Florida. Beyond Live Science, Lanese's work has appeared in The Scientist, Science News, the Mercury News, Mongabay and Stanford Medicine Magazine, among other outlets. Based in NYC, she also remains involved in dance and performs in local choreographers' work.